Business

Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program

Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’

articleSolana CompanyAugust 7, 20233/company/helius-medical-technologies-inc-class-a/news/helius-medical-technologies-inc-announces-participation-of-montefiore-medical-center
Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program

About this update from Solana Company

[{"type":"text","content":"Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS Therapy™ for gait improvement in Multiple Sclerosis\nNEWTOWN, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the addition the Montefiore Medical Center (“Montefiore”) to its PoNS Therapeutic Experience Program (“PoNSTEP”). Montefiore joins five other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (“PoNS®”) therapy in patients with multiple sclerosis (“MS”). Montefiore’s participation in the study will be held at the Burke Rehabilitation Center and led by Dr. Christopher Langston, medical director of The Madlyn Borelli Multiple Sclerosis Center at Montefiore Nyack Hospital. “Dr. Langston is a renowned clinical researcher of current and advanced topics in MS management and patient-centered care. His interest in PoNS Therapy has led him to be one of the first PoNS prescribers and his growing experience with this therapy, along with a long-standing commitment to improving MS patients’ condition, makes him a remarkable contributor to the PoNSTEP study,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. “The MS patients we treat are often in the prime of their lives. At Montefiore, we believe it’s important to understand all MS treatments available in order to guide our patients in choosing their best path. We strive to help them navigate their illness by exposing them to innovative therapies as well as giving them the opportunity to participate in advanced clinical trials. I’ve been an early adopter of PoNS Therapy to help my patients improve their gait and I'm excited to join the study,” stated Dr. Langston. About Montefiore Medical Center As the academic medical center and University hospital for Albert Einstein College of Medicine, Montefiore Medical Center is nationally recognized for clinical excellence—breaking new ground in research, training the next generation of healthcare leaders, and delivering science-driven...

More updates from Solana Company